NCT Number: NCT02121340
Collaborative Care for Depression and Diabetic Retinopathy in African Americans
In this feasibility/pilot study, we will develop, refine, and evaluate the feasibility of a novel mental health/ophthalmologic intervention called, "Collaborative Care for Depression and Diabetic Retinopathy" (CC-DDR), which aims to treat depression and lower HbA1C in older African Americans with mild-to-moderate diabetic retinopathy (DR) and comorbid depression.
Looking for future studies?
Notify MeKey information
Conditions
Age range
65 year and older
Sex eligibility
All sexes
Study type
Interventional
Phase
Not applicable
Primary location
Thomas Jefferson University, Philadelphia, Pennsylvania, United States
About this study
The Specific Aims are:
- To develop the CC-DDR treatment protocol. This will involve:
- Creating an initial version of the CC-DDR treatment protocol.
- Refining the protocol based on input from an expert panel with expertise in DR, depression, and culturally relevant interventions for diabetes in older African Americans.
- Developing a tool to assess interventionist treatment adherence and competence.
- To conduct an open trial of CC-DDR with 40 participants who have poorly controlled diabetes, depression, and mild or moderate DR. During this open trial we will:
- Evaluate the feasibility of CC-DDR.
- Refine the CC-DDR treatment protocol by incorporating feedback from participants, community health care workers (CHWs), ophthalmologists, and the expert panel.
- Refine procedures for recruitment and retention, outcome assessment, monitoring treatment fidelity, CHW training and supervision, quality assurance, and study administration, based on input from investigators, CHWs, participants, and the expert panel.
- Examine CC-DDR's impact on depression severity; diabetes self-management practices; HbA1C level; blood pressure; adherence to the ophthalmologist treatment plan; vision function; quality of life; and satisfaction with CC-DDR.
- To complete a Manual of Procedures that characterizes all aspects of the planned efficacy trial of CC-DDR.
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- African-American race
- age ≥ 65 years
- type 2 diabetes
- mild or moderate nonproliferative DR with or without macular edema
- depressive symptoms (i.e., Patient Health Questionnaire-9 score ≥5)
- HbA1C ≥ 7.0%
Exclusion criteria
- treated proliferative DR
- global cognitive impairment (i.e., Mini Mental Status score ≤ 20)
- psychiatric diagnosis other than depression
- treatment for depression started in the previous 3 months
- life expectancy under 2 years
Treatment and study plan
Primary outcomes
-
Hemoglobin A1c
Time frame: 12 months
Change in hemoglobin A1c from baseline to 12 months
Other outcomes
-
Depression
Time frame: 12 months
Improvement in depressive symptoms from baseline to 12 months
-
Progression of diabetic retinopathy
Time frame: Baseline to 12 months
-
Diabetes self management
Time frame: 12 months
Improvement from baseline to 12 months
Sponsors and collaborators
Lead sponsor
Thomas Jefferson University
Other
Collaborators
- Wills Eye
Registry information
Acronym: CC-DDR
Important dates
- Study start
- 2014
- Primary completion
- 2018
- Study completion
- 2018
- First posted
- Apr 23, 2014
- Registry last updated
- Feb 21, 2019
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Diabetic Retinopathy as a Marker of Cognitive Dysfunction and Depression
NCT04610749
Behavior, Behavioral Symptoms
Odense, Fyn, Denmark
View Trial DetailsAI Prediction of Treatment Response in DME
NCT07707856
Cardiovascular Diseases, Diabetes Complications
Banhā, Benha, Egypt
View Trial DetailsAI for the Detection of Retinal Disease and Glaucoma in Patients With Diabetes Mellitus in Primary Care
NCT04132401
Age-Related Macular Degeneration, Cardiovascular Diseases
Manresa, Barcelona, Spain
View Trial DetailsINflammatory MediatorS in the PathophysIology of Diabetic REtinopathy Study
NCT04505566
Cardiovascular Diseases, Diabetes Complications
Nashville, Tennessee, United States
View Trial Details